A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Tralokinumab (Primary)
- Indications Atopic dermatitis
- Focus Registrational; Therapeutic Use
- Acronyms ECZTRA 3
- Sponsors LEO Pharma
- 28 Feb 2018 According to a LEO Pharma media release, the first patient has been enrolled in this trial.
- 28 Feb 2018 Status changed from not yet recruiting to recruiting, according to a LEO Pharma media release.
- 14 Feb 2018 Planned initiation date changed from 8 Feb 2018 to 22 Feb 2018.